BC Week In Review | Sep 28, 2015
Clinical News

Taxis Pharmaceuticals preclinical data

Taxis said oral TXA709 plus cefdinir showed synergistic activity against all MRSA strains tested in a mouse model of peritonitis systemic infection. Additionally, the combination significantly reduced detectable frequency of resistance (FOR), a measure of...
BioCentury | Oct 30, 2006
Regulation

On the market

On the market Product Class Amoxil amoxicillin (GlaxoSmithKline) Beta-lactam Augmentin amoxicillin/clavulanate (GlaxoSmithKline) Beta-lactam Omnicef cefdinir (Abbott) Beta-lactam Ceftin cefuroxime (GlaxoSmithKline) Beta-lactam Cefzil cefprozil (Bristol-Myers) Beta-lactam Vantin cefpodoxime (Pfizer) Beta-lactam Avelox moxifloxacin (Bayer) Fluoroquinolone Cipro ciprofloxacin...
BC Extra | Jul 9, 2004
Top Story

Abbott meets Street

ABT reported second quarter EPS of $0.54, meeting the Street's estimate and up 15% from EPS of $0.47 in the same period last year. Second quarter global sales were $4.7 billion, up 14% compared with...
Items per page:
1 - 3 of 3